- Cell Biology
- Product Type
- Research Area
- New Products
- About Tocris
- Contact Us
Neuroscience is the study of the nervous system - one of the major mammalian systems responsible for sustaining life. The central nervous system (CNS) and peripheral nervous system (PNS) work in concert to coordinate basic functions such as moving and breathing, as well as 'higher order' functions including thought, speech and emotion.
The incidence of degenerative neurological disorders, such as Alzheimer's disease and Parkinson's disease, is increasing worldwide. As these diseases are typically associated with advancing age, this increase is partly due to rising life expectancy. However, environmental factors such as pesticide and insecticide use, are being discussed as possible etiologies for these neurodegenerative diseases.
Neurological diseases can be classified according to their etiology. They can be caused by:
At present pharmacological interventions for many neurological diseases, especially the degenerative conditions, are limited and predominantly restricted to alleviation of symptoms. The understanding of the nervous system, and prevention and treatment of neurological disorders represents one of the critical goals of medical research today. Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and multiple sclerosis are currently the focus of intense neuroscience research.
When derived from human cells, cerebral organoids enable the investigation of neurophysiology and disease using in vitro and in vivo methods that cannot be used in humans. This blog post describes how cerebral organoids can be used in neurodevelopment, neurodegeneration and virology research.Read Now!
Tocris offers the following scientific literature for Neuroscience Research to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
Written by Ian Martin, Norman Bowery and Susan Dunn, this review provides a history of the GABA receptor, as well as discussing the structure and function of the various subtypes and the clinical potential of receptor modulators; compounds available from Tocris are listed.
Produced by Tocris, the chemogenetics research bulletin provides an introduction to chemogenetic methods to manipulate neuronal activity. It outlines the development of RASSLs, DREADDs and PSAMs, and the use of chemogenetic compounds. DREADD ligands and PSEMs available from Tocris are highlighted.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.